Pivot Inks Manufacturing Deal with Bio V Pharma

Cannabis Investing News

Pivot Pharmaceuticals signed a contract manufacturing agreement with Bio V Pharma to provide the manufacturing, labeling, packaging and supply for Pivot’s bio-cannabis product pipeline.

Pivot Pharmaceuticals (CSE:PVOT; OTCQB:PVOTF) signed a contract manufacturing agreement with Bio V Pharma to provide the manufacturing, labeling, packaging and supply for Pivot’s bio-cannabis product pipeline.

As quoted in the press release:

BioV is a Quebec-based full-service manufacturer of pharmaceutical and nutraceutical products including vitamins, botanical products, food and veterinary supplements and specializes in capsules, tablets, liquids and semi-solids delivered in a variety of packaging formats.
Dr. Patrick Frankham, Pivot’s CEO, stated “We are excited to have chosen Bio V Pharma as our Canadian manufacturing partner at this important time in Pivot’s history. Consumers and regulators will demand high-quality products that are manufactured in cGMP facilities by a knowledgeable and experienced team. BioV has a track record of supplying retail pharmacy chains, including Shoppers Drug Mart and London Drugs, with products meeting the highest quality standards. We continue to execute on our business plan to monetize our platform technologies by commercializing our suite of premium, science-based cannabis products in key markets.”

Click here to read the full press release.

Source: www.newswire.ca

Cannabis Investing